Part 7F - Further Information 7F.01 The purpose(s) for which the entity is issuing the securities Proceeds from the Placement will support the continuation of the Company¿s drug development pipeline, including CannEpil® and CimetrA® in the US and EU markets.
Reading over the last FOUR Years and more of this company and previously under the OLD Company name -- it would appear that the Funding Creativity mixed with --- Possible deals , partners, developments and products -- even with moving to UK and slight change of Management --- seems the ingenious ways of getting funding from share holders -- has not diminished as an art form..
Alway DYOR
RGT Price at posting:
30.5¢ Sentiment: None Disclosure: Not Held
